You are here: Industry Insights > AstraZeneca

News List

AstraZeneca gets breakthrough status for Enhertu to treat NSCLC pharmaceutical-technology
May 20, 2020
AstraZeneca and its partner Daiichi Sankyo have received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for Enhertu (trastuzumab deruxtecan) to treat non-small cell lung cancer (NSCLC).
AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation pharmatimes
May 19, 2020
AstraZeneca's and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with a particular form of lung cancer.
Lynparza, Bevacizumab Combination Approved for HRD-Positive Advanced Ovarian Cancer in the US americanpharmaceuticalreview
May 15, 2020
AstraZeneca and Merck announced that Lynparza (olaparib) in combination with bevacizumab has been approved in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
AstraZeneca Recovers Global Rights to brazikumab from Allergan americanpharmaceuticalreview
May 14, 2020
AstraZeneca has completed a previously communicated agreement to recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan.
US nod for Lynparza in HRD-positive advanced ovarian cancer pharmatimes
May 12, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been cleared in the US for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer.
AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug pharmaceutical-business-review
May 12, 2020
AstraZeneca and Daiichi Sankyo have secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for its Enhertu.
AstraZeneca regains global rights to brazikumab from Allergan pharmaceutical-technology
May 12, 2020
AstraZeneca has regained global rights to brazikumab (previously MEDI2070) from Allergan, following the termination of a prior licensing deal between the companies.
AstraZeneca, Oxford University Announce Agreement for COVID-19 Vaccine americanpharmaceuticalreview
May 07, 2020
AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
AZ delivers strong first quarter pharmatimes
May 05, 2020
AstraZeneca says it has delivered “a quarter of strong revenue and profit growth, reflecting the immense efforts of supply chain, commercial and other colleagues around the world to get vital medicines to patients”.
AstraZeneca and Oxford University partner on Covid-19 vaccine pharmaceutical-technology
April 30, 2020
AstraZeneca has signed an agreement with the University of Oxford to develop and distribute the university’s Covid-19 vaccine candidate, ChAdOx1 nCoV-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page